Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
Jingran Ji(Northwestern University), Jonathan W. Riess(University of California Davis Medical Center), Collin M. Blakely(City College of San Francisco), Laura A. Huppert(University of California, San Francisco), Andrew J. Piper‐Vallillo(Harvard University), Hatim Husain(University of California, San Diego), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Joel W. Neal(Stanford Medicine), Heather A. Wakelee(Palo Alto Institute), Geoffrey R. Oxnard(Foundation Medicine (United States)), Matthew A. Gubens(University of California, San Francisco), Jacqueline V. Aredo(Stanford University), Susan L. Stewart(UC Davis Comprehensive Cancer Center), Zofia Piotrowska(Global Cancer Institute), Melisa L. Wong(UCSF Helen Diller Family Comprehensive Cancer Center), Rosemary Cobb(Massachusetts General Hospital), Justin Chen(New York Proton Center), Julia Rotow(University of California, San Francisco)
Cited by 18
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k